Tag: amyloidosis

The U.S. Food and Drug Administration today approved Tegsedi (inotersen), a novel therapy for the treatment of hereditary TTR amyloidosis polyneuropathy. (more…)

Global Genes, a disease advocacy organization, recently interviewed ARC CEO Isabelle Lousada as part of their Rare Leader Profile series. The series gives insight into people who lead rare disease organizations. Below is a copy Isabelle's Q&A that was featured...

Every December thousands of physicians, researchers and healthcare professionals gather for the biggest hematology event of the year: the American Society of Hematology (ASH) meeting. ASH is the world’s largest professional society serving clinicians and scientists around the world working...

The Amyloidosis Research Consortium (ARC) recently launched the latest version of the My Amyloidosis Pathfinder (MAP) tool. This groundbreaking tool was created to help connect amyloidosis patients to appropriate treatment centers and clinical trials for their disease. The latest updates...